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Bimolecular ﬂuorescence complementationAggregation and ﬁbril formation of human alpha-Synuclein (αS) are neuropathological hallmarks of Parkinson's
disease and other synucleinopathies. Themolecularmechanisms ofαS aggregation and ﬁbrillogenesis are largely
unknown. Several studies suggested a sequence of events from αS dimerization via oligomerization and pre-
ﬁbrillar aggregation to αS ﬁbril formation. In contrast to αS, little evidence suggests that γS can form protein
aggregates in the brain, and for βS its neurotoxic properties and aggregation propensities are controversially
discussed. These apparent differences in aggregation behavior prompted us to investigate the ﬁrst step in
Synuclein aggregation, i.e. the formation of dimers or oligomers, by Bimolecular Fluorescence Complementation
in cells. This assay showed some Synuclein-speciﬁc limitations, questioning its performance on a single cell level.
Nevertheless, we unequivocally demonstrate that all Synucleins can interact with each other in a very similar
way. Given the divergent aggregation properties of the three Synucleins this suggests that formation of dimers
is not predictive for the aggregation of αS, βS or γS in the aged or diseased brain.
© 2015 Elsevier B.V. All rights reserved.1. Introduction
Since the discovery of alpha-Synuclein (αS) as main constituent of
the Lewy body in 1997 [1], this protein has been put under the spotlight
of intensive investigation in the ﬁeld of neurodegenerative diseases.αS
is highly abundant in the mammalian brain, with subcellular localiza-
tion in the nucleus, presynaptic terminals and mitochondria of neurons
[2,3]. Its physiological role is still enigmatic, but a multitude of putative
functions have been suggested, i.e. involvement in vesicle regulation
(e.g. vesicle biogenesis, trafﬁcking, and fusion), chaperone activity for
synaptic proteins, and modulation of synaptic transmission [4].
In solutionαS appears to be a proteinwithout ordered tertiary struc-
ture [5], but it forms distinct alpha-helical structures upon membrane
binding [6,7], and β-sheets during aggregation processes [8,9]. Fibril
formation appears to take place via intermediate states of dimers, olig-
omers, and protoﬁbrils,ﬁnally resulting in the formation of Lewy bodies,
which are the pathological hallmark of a variety of synucleinopathies
including Parkinson's disease [10]. Whether αS physiologically exists
as a monomer or adopts a stable tetrameric state is controversially
discussed [11,12]. Increases in αS protein levels which are observed in
genomicmultiplications of theαS gene (SNCA)were suggested to resultin; γS, gamma-Synuclein; BiFC,
al part of Venus; VC, C-terminal
: +49 0 551 39 14302.in abnormal aggregate formation and neuronal degeneration in vitro
[13–15] and in vivo [16,17]. Human αS wild type and disease-
associated αS mutants readily assemble into ﬁlaments in vitro [18]
and disease-associated mutants of αS show accelerated aggregation
and ﬁbril formation in vitro [19,20].
The Synuclein protein family consists of two further proteins very
closely related to αS, with also unresolved physiological functions.
Beta-Synuclein (βS) is an abundant protein in mammalian CNS, while
gamma-Synuclein (γS) is predominantly expressed in PNS. Comparison
of the aggregation propensities ofαS, βS, and γS revealed thatαS forms
ﬁbrils most rapidly whereas βS and γS ﬁbrillize much slower or not at
all under the same experimental conditions in vitro [8,21,22]. These dif-
ferences were attributed to structural characteristics of the Synuclein
isoforms, in particular the hydrophobic NAC domain in αS which was
proposed to be intimately involved in αS aggregation processes
[23–25]. βS lacks most part of the NAC domain which was suggested
to slowdown its aggregation and to cause βS interference with αS ﬁbril
formation [26,27,21]. γS, although structurally similar to αS, was pro-
posed to be protected from aggregation due to increased structural sta-
bility in the amyloid forming region [28]. However, posttranslational
modiﬁcations, e.g. oxidation, seem to drive oligomerization and aggre-
gation of αS in vitro [4] and similar observations were made for γS [29].
Lewy bodies and Lewy neurites are immunopositive for αS [1].
Although some extranigral neuritic pathology was shown, human βS
and γS have not been detected in Lewy structures or glial cytoplasmic
inclusions of multiple system atrophy so far [30–32]. The general con-
sensus in the ﬁeld is that aggregation is a main pathogenic feature of
Fig. 1.Generation of cellularmodels based onBimolecular Fluorescence Complementation
(BiFC). (A) Schematic diagram of Venus-based BiFC constructs. VN-αS, N-terminal part of
Venus (VN, amino acids 1 to 158) fused to the N-terminus of full-length human alpha-
Synuclein (αS). αS-VC, C-terminal part of Venus (VC, amino acids 159 to 239) fused to
the C-terminus of full-length αS allowing reconstitution of Venus ﬂuorescence in case of
antiparallel orientation of the two αS molecules. (B) Transfection of HEK293 cells with
the indicated constructs and DsRed2-mito as internal control. ICC with αS-speciﬁc
primary antibody and Alexa647-conjugated secondary antibody. Representative images
show the complemented Venus signal (BiFC), αS protein (Alexa 647), and the internal
control (DsRed2). Scale bar 20 μm. (C) Determination of the corrected total cell
ﬂuorescence (CTCF) of the BiFC signal versus internal control DsRed2 for all samples
from 10 images of N ≥ 5 independent experiments. The BIFC signal in VN-αS + αS-VC
is signiﬁcantly higher than in the controls. Mean values ± SD; ***, P b 0.001.
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animal models using transgene expression [34] or viral delivery [35],
and in cellular models [13,36]. Some reports also point to a role of en-
dogenous αS, βS, and γS which hampers the interpretation of results
from animal studies [37–40].Wild-typeβS has been found to be protec-
tive in various settings against αS-mediated neurodegeneration [26,27,
41]. However, recent evidence was provided for proteinase K-resistant
human wild type βS aggregates and toxicity in dopaminergic neurons
in vivo upon overexpression [42]. Interestingly, expression of human
βS with a point mutation that was described in rare cases with DLB
induced neurodegeneration in a transgenic mouse model of DLB
[43,44]. Very recently, pathological aggregation of human γS was
suggested to contribute to the pathogenesis of ALS [32].
The evident differences in protein domain structure, aggregation
behavior and toxicity among the three family members αS, βS,
and γS prompted us to investigate the initial step in aggregation,
namely protein dimerization, using the Bimolecular Fluorescence
Complementation (BiFC) technique. In the BiFC system, expression of
two non-ﬂuorescent fragments of a ﬂuorophore fused to potential
interaction partners was used to visualize the location of protein inter-
actions in living cells [45,46]. BiFC was primarily applied for the investi-
gation of heterodimeric protein interactions. Subsequently, several
studies employed this technique also for the analysis of protein
homodimerization and oligomerization [14,47]. Initial studies used the
ﬂuorophore GFP for BiFC. Later, YFP/mVenus, CFP and mCherry, served
as alternative ﬂuorophores, and were used in multicolor BiFC to enable
the visualization of interactions between different proteins in the same
cell and comparison of the efﬁciencies of complex formation with alter-
native interaction partners [48]. In the current study we show that the
BiFC assay shows some Synuclein-speciﬁc limitations, but nonetheless
allowed to demonstrate that all Synucleins show almost identical
dimerization propensities, suggesting that Synuclein dimerization is
not predictive for eventual Synuclein aggregation.
2. Material and methods
2.1. Bimolecular Fluorescence Complementation (BiFC)
The BiFC technique in the current study is based on the expression of
two non-ﬂuorescent fragments of the Venus ﬂuorophore fused to
human Synuclein isoformsα, β, and γ in order to visualize the localiza-
tion of protein dimerization in cells. To that end, Venus cDNA was
ampliﬁed by PCR to generate the N-terminal (VN) and C-terminal
(VC) parts of the ﬂuorophore. VN was introduced via NheI and AﬂII re-
striction sites, VC via XhoI and XbaI restriction sites into the pcDNA3.1
vector (Life Technologies, Carlsbad, CA, USA) to generate VN and VC
controls. Synuclein cDNA was introduced 3′ terminally of VN via AﬂII
and XhoI restriction sites including a linker of 36 nucleotides between
VN and Synuclein to generate plasmids encoding VN-αS, VN-βS, and
VN-γS. The linker encodes for a glycine-rich sequence that serves as
ﬂexible tether between the C-terminus of the VN fragment and the
N-terminus of Synuclein. Synuclein cDNA was introduced 5′ terminally
of VC via AﬂII and XhoI restriction sites to generate αS-VC, βS-VC, and
γS-VC. Similarly, a small linker between the C-terminus of Synuclein
and the N-terminus of the VC fragment provides ﬂexibility of the two
segments for ﬂuorophore assembly as well as dimer formation. VC
was excised via XhoI and XbaI restriction sites from the αS-VC plasmid,
and the vector was blunted and religated to generate untagged αS
control.
Cells were transfected with the different BiFC constructs and the in-
ternal control pDsRed2-Mito (BD Biosciences, Franklin Lakes, NJ, USA)
as described in Section 2.2. Cells were ﬁxed and stained 36 h post-
transfection (Section 2.4). For all quantiﬁcations in the current study,
images were acquired under non-saturating conditions using an
Axioplan 2 equipped with Plan Neoﬂuar 10×/0.30 Ph1, AxioCam
HRm camera and AxioVision SE64 Rel. 4.9 software (Carl Zeiss, Jena,Germany). Images were analyzed using ImageJ 1.45 s software.
Corrected total cell ﬂuorescence (CTCF) was calculated as Integrated
Density of selected cells subtracted by the multiplication of Area of
selected cells and Mean ﬂuorescence of background readings [49,50].
CTCF of the complemented Venus ﬂuorescence (BiFC) was referred to
the CTCF of the internal control DsRed2 in order to exclude artifacts
from differences in transfection efﬁciency, protein expression levels,
and cell coverage. For each condition, the area (901 μm×675 μm)of ap-
proximately 200 transfected cells per image from 10 images per exper-
imental condition was quantiﬁed. Statistical analysis was carried out by
one-way ANOVA followed by Tukey's post hoc test from N ≥ 3
independent experiments.
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HEK293, H4, and HeLa cells were cultured in DMEM (Sigma, St.
Louis, MO, USA) supplemented with 10% fetal bovine serum (FBS;
Biochrom, Berlin, Germany) and 100 units penicillin/100 μg streptomycin
per ml (Sigma, St. Louis, MO, USA) at 37 °C and 5% CO2. Cells were plat-
ed at 15,000 cells/cm2 on poly-D-lysine (Sigma, St. Louis, MO, USA)
-coated glass cover slips. After 24 h, HEK293 cells and HeLa cells wereFig. 2. False-positive BiFC in the control condition VN-αS + VC. (A) Co-expression of VN-αS w
internal control. ICC with αS-speciﬁc primary antibody and Alexa647-conjugated secondary a
(Alexa 647), and the internal control (DsRed2), depicting cells with high and low BiFC signals
the BiFC sample VN-αS + αS-VC (left) and the control sample VN-αS + VC (right) with BiFC
to 0–233 to visualize weak ﬂuorescence intensities. Scale bar 100 μm. Frequency distribution o
The mean gray values were determined individually for all transfected cells within the image a
sities in cells of the BiFC sample VN-αS + αS-VC (red ﬁll) and the control condition VN-αS +transfected with the calcium phosphate method in 24-well format. In
brief, 0.66 μg total DNA was diluted in 33 μl 250 mM CaCl2, mixed
with 33 μl 2xHBS (280 mM NaCl, 50 mM HEPES, 12 mM Glucose,
10mMKCl, 1.5mMNa2HPO4, pH7.04), incubated for 50 s at room tem-
perature, and stopped with 533 μl DMEM/2% FBS. H4 cells were
transfected with Fugene (Promega, Madison, WI, USA) according to
the manufacturer's instructions using 0.5 μg DNA and 1.5 μl Fugene
per 24-well. After 12 to 14 h, transfection mix was exchanged by cellith αS-VC or co-expression of VN-αS with VC alone (not fused to αS). DsRed2 served as
ntibody. Representative images show the complemented Venus signal (BiFC), αS protein
for each experimental condition. Scale bar 20 μm. (B) Representative overview images of
/DsRed2 ratios of 1.40 and 0.42, respectively. The threshold values of the images were set
f mean gray values (BiFC) in transfected cells in the two representative overview images.
rea and plotted on a histogram. The analysis reveals a large overlap of ﬂuorescence inten-
VC (gray solid line). AU, arbitrary units.
Fig. 3. Aberrant VN-αS protein levels in cells. Single or co-transfection of HEK293 cells
with plasmids encoding untagged αS, the non-ﬂuorescent fragments of Venus VN and
VC (not fused to any Synuclein), and the fusion proteins VN-αS + αS-VC. Cells were
lysed in RIPA buffer, and equal protein amounts were separated by 15% Tris-glycine
SDS-PAGE. Use of αS speciﬁc antibody (upper panel and graph) allowed the direct
comparison of protein levels in cells expressing VN-αS, αS-VC and untagged αS. Mean
values ± SD. VN was additionally stained with a GFP antibody (middle panel). AU,
arbitrary units.
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SDS-PAGE or immunocytochemistry.
2.3. SDS-PAGE and immunoblotting
Cells were lysed in RIPA buffer (20 mM sodium phosphate, 150 mM
NaCl, 1% Triton X-100, 0.5% sodium deoxycholate, 0.5% SDS, protease in-
hibitors, pH 7.4) and sonicated with 5 one-second pulses at 10W. 20 to
50 μg protein according to BCAproteinmeasurement (ThermoScientiﬁc,
Rockford, IL, USA) were subjected to 15% Tris-Glycine SDS-PAGE and
transferred to nitrocellulose membranes (Applichem, Darmstadt,
Germany). Membranes were blocked in TBS-T + 5% milk, incubated
with primary antibodies at 4 °C over night, incubated with HRP-
conjugated secondary antibodies and detected with enhanced chemilu-
minescence (ImmobilonWestern,Millipore, Billerica, MA, USA). Images
were performed and quantiﬁed using ChemiDoc XRS+with Image Lab
Software (BIO-RAD, Hercules, CA, USA).
2.4. Immunocytochemistry (ICC)
Cells were washed in PBS and ﬁxed in PBS/4% paraformaldehyde at
room temperature for 10 min. Cells were treated with PBS/0.5% Triton
X-100 for 20 min, blocked in PBS/1.5% normal goat serum for 30 to
60 min, and incubated with primary antibodies at 4 °C over night in a
humid chamber. After repeated washes in PBS, cells were incubated
with Alexa647-conjugated secondary antibodies at room temperature
for 2 h, stained with 2 μg/ml 4′,6-Diamidin-2-phenylindol for 2 to
3min, andmounted in Fluoromount G (Southern Biotech, Birmingham,
AL, USA).
2.5. Antibodies
The following primary antibodieswere used at 1:500 to 1:1000 dilu-
tions:αS BD610787 (BD Biosciences, Franklin Lakes, NJ, USA),β-tubulin
(Sigma, St. Louis, MO, USA), GFP (VC) (Roche, Mannheim, Germany),
GFP-FL (VN and VC) (SCBT, Dallas, TX, USA). Secondary Alexa647-
conjugated goat anti-mouse or anti-rabbit antibodies (Jackson
ImmunoResearch, West Grove, PA, USA) were used at 1:500 dilutions,
and secondary HRP-conjugated goat anti-mouse or anti-rabbit antibod-
ies (SCBT, Dallas, TX, USA) were used at 1:4000 to 1:5000 dilutions.
3. Results and discussion
3.1. Generation of cellular models based on Bimolecular Fluorescence
Complementation
We designed and generated several BiFC constructs on the basis of
the Venus ﬂuorophore due to the advantage of relative efﬁciency of
folding and maturation at 37 °C versus lower temperatures [51]. The
site of fragmentation was located in the loop between the 7th and 8th
β strand, at amino acid position 158 according to the sequence of the
full-length protein (Fig. 1A). The 5′ cDNA fragment of Venus and full-
length human αS cDNA were cloned in order to obtain a protein that
consists of the bigger N-terminal fragment of Venus (VN) fused to the
N-terminus of αS (subsequently named “VN-αS”). Cloning of full-
length human αS cDNA and the 3′ cDNA fragment of Venus encode
the smaller C-terminal fragment of Venus fused to the C-terminus of
αS (subsequently named “αS-VC”). Corresponding constructs were
generated for βS and γS. Several studies support an antiparallel interac-
tion of two αS molecules [14,9] prompting us to design the BiFC con-
structs in favor of this orientation.
We observed complementation of Venus ﬂuorescence upon co-
expression of VN-αS and αS-VC in co-transfected cells but not in the
single transfected controls (VN-αS only or αS-VC only), suggesting
that Synuclein dimerization can be readily visualized with the BiFC
technique (Fig. 1B, C). A human αS-speciﬁc antibody (Fig. 1B,Alexa647) revealed an even distribution of VN-αS and/orαS-VCmono-
mers within cells. The complemented Venus signal representing αS
dimers appeared to be predominantly nuclear in many cells, but was
found to be localized mainly cytoplasmically or evenly distributed in
others.3.2. Occurrence of false-positive BiFC requires additional controls
In order to demonstrate interactions of the Synucleins unambigu-
ously we included additional controls, which have thus far not been
used in any published studies investigating αS dimerization by BiFC
(Figs. 2, S1).
These additional controls allowed us to detect substantial false
positive BiFC especially after co-expression of VN-αS with VC alone
(not fused to any Synuclein) and to some extent with αS-VC and VN
alone. In accordance to other studies [52], the overall noise/background
signal intensities were estimated to reach 20–50% of the protein–
protein interaction (Fig. S1). Intriguingly, on basis of single cells we
detected ﬂuorescence levels of the VN-αS + VC-only controls to reach
that of the brightest cells transfected with VN-αS + αS-VC (Fig. 2A).
We observed a large overlap of ﬂuorescence intensities in cells of both
samples (Fig. 2B). This means that a remarkable number of cells in
the control condition VN-αS + VC showed the same ﬂuorescence com-
plementation as cells expressing VN-αS + αS-VC. This circumstance
puts into question the reliability of investigations of protein interaction/
dimerization on a single cell level, for which the BiFC technique was
initially implemented for [45,46], at least in case of the Synucleins.
Fig. 4. Homo- and heterodimerization of human Synucleins. (A) Similar to αS, VN and VC
fusion proteins of human βS and human γS were generated. HEK293 cells were
transfected with various combinations of these BiFC constructs and the internal control
DsRed2. Representative images show the complemented Venus signal in cells expressing
VN-αS (left column), VN-βS (middle column), and VN-γS (right column) together with
αS-VC (upper row), βS-VC (middle row), and γS-VC (bottom row). Scale bar 20 μm.
(B) Quantitative analysis of the BiFC signal referred to the internal control DsRed2 for all
samples from 10 images of N ≥ 3 independent experiments shows no signiﬁcant (n.s.,
P N 0.05) differences among the various Synuclein combinations. Mean values ± SD.
(C) Similar protein expression of αS, βS, and γS constructs was conﬁrmed by western
blot analysis. The use of two different speciﬁc antibodies recognizing VNand VC fragments
allowed the comparison of protein levels between the three Synuclein isoformsα,β, andγ
but not between VN-xS and zS-VC constructs. Mean values ± SD. AU, arbitrary units.
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Furthermore, signal-to-noise ratios vary among different mammalian
cell lines. Many in vitro αS aggregation studies were based on human
neuroglioma H4 cells [53,54,14,55], a cell line that showed the highest
false-positive ﬂuorescence in our BiFC experiments (Fig. S2). A putative
reason for the high level of false-positive BiFC ﬂuorescence in Synuclein
dimerization assays is shown in Fig. 3.
Fusion of VN to αS resulted in roughly 5-fold higher protein levels
than αS-VC and even more than untaggedαS under all conditions test-
ed (Fig. 3), which may reﬂect differences in stability or degradation of
these proteins. Similar observations were made with VN-βS and
VN-γS (not shown). Fusion to VN approximately doubles the size of
αS which may contribute to these alterations, as observed also with
intact (full-length) ﬂuorophores and corresponding fusion proteins
[56–58]. These elevated levels of VN-αS protein were detected at early
time points after transfection and sustained high throughout the dura-
tion of the experiments. Thus, our observations suggest that high levels
of VN-αS can sequester VC to complement ﬂuorescence in the absence
of a Synuclein dimerization partner. This assumption is supported by
several other studies that also pointed to the limitation of BiFC due to
trapping of particular protein–protein interactions and stabilization
of the (heterodimeric) protein complex after reconstitution of the
ﬂuorophore [46,59,60].
3.4. αS, βS, and γS form homo- and heterodimers
With the described limitations of BiFC in mind andwith appropriate
controls at hand, we continued with the co-expression of VN-βS
together with βS-VC and VN-γS together with γS-VC in order to inves-
tigate differences in the dimerization behavior of the Synuclein family
members (Fig. 4). Dimerization ofαS is suggested to be a keymolecular
step in the aggregation of αS [61–63]. Since robust aggregation of βS,
but not γS, was shown as well [42], we expected to observe differences
in BiFC in cells expressing the αS, βS, and γS constructs, respectively.
Interestingly, the complementation of Venus ﬂuorescence using βS
and γS constructs was comparable to that of αS (Fig. 4A). Moreover,
all combinations ofαS, βS, and γS constructs fused to VN or VC resulted
in complementation of Venus ﬂuorescence.
Representative images show that the subcellular distribution of
the Venus ﬂuorescence was different among the diverse combinations,
in particular nuclear exclusion and perinuclear enrichment of the
signal when VN-γSwas employed (Fig. 4A, right column). The apparent
nuclear exclusion observed in many cells where VN-γS was used as a
dimerization partner most likely depends at least partially on the
over-abundance of VN-fusion proteins over their VC-fusion partners.
This subcellular sequestration was less obvious in case of combining
VN-αS (or VN-βS) with VC-γS. However, in this situation αS (βS) is
overabundant over γS, making it impossible to describe one of the
two different subcellular localizations of the dimerized protein as the
more likely one. In addition, as already described for αS homodimers
(Section 3.1), preferential localization of BiFC was not consistently
observed in all cells. Each homodimeric or heterodimeric combination
of the αS, βS, and γS BiFC constructs produced Venus ﬂuorescence in
different subcellular compartments e.g. nuclear, cytosolic, perinuclear,
and evenly distributed. Similar observations were made with a pan-
Synuclein antibody recognizing the monomeric forms of αS, βS, and
γS (data not shown).
These results clearly demonstrate that despite the beneﬁts of BiFC to
study protein–protein interactions, at least in case of the Synucleins
great care and appropriate controls are necessary for interpretation of
results.
The ﬂuorescence yield of each dimer was determined by calculation
of the corrected total cell ﬂuorescence (CTCF) of the BiFC signal referred
to the CTCF of the internal control DsRed2 from several hundred cells
per experimental condition (see Section 2.1). Quantiﬁcation of the
Fig. 5.Homodimerization propensities ofαS, βS, and γS determined by BiFC quantiﬁcation from a large number of cells. The indicated BiFC constructs and DsRed2 as internal control were
expressed in HEK293 cells. Determination of corrected total cell ﬂuorescence of the BiFC signals referred to the internal control DsRed2 for all samples from 10 images per experimental
condition of N ≥ 4 independent experiments. For all three Synuclein isoforms, the BIFC signal in VN-Synuclein + Synuclein-VC is signiﬁcantly higher than in the corresponding control
conditions. Mean values ± SD; **, P b 0.01; ***, P b 0.001.
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between the various Synuclein combinations (Fig. 4B). Equal protein ex-
pression of the Synuclein constructs was veriﬁed by western blotting
using antibodies against the Venus fragments VN and VC (Fig. 4C).
Taken together, these experiments were suggestive of dimerization
properties to be almost identical between all human Synuclein family
members, irrespective of an existing NAC domain (lacking in βS) or
the propensities of the three different proteins to form proteinase
K-resistant aggregates in the brain in vivo, and irrespective if homo- or
heterodimers were formed. This surprising ﬁnding argues for the hy-
pothesis that all Synucleins can closely physically interact without
necessarily forming aggregation-prone material.3.5. γS has homodimerization propensities similar to αS and βS
Since false positive BiFC was observed in many other studies, the
analysis of Synuclein dimerization and oligomerization using BiFC
might be useful as long as it is properly controlled for the appearance
of self-assembly and interaction-independent false-positive ﬂuorescent
signals.We therefore analyzed the signal-to-noise ratios for all isoforms
using VN-Synuclein + Synuclein-VC as sample for protein–protein
interaction and the controls VN-Synuclein + VC and Synuclein-
VC+ VN for false positive noise (Fig. 5). As mentioned above, for quan-
tiﬁcations in the current study the corrected total cell ﬂuorescence from
several hundred cells per experimental condition was determined for
Venus (BiFC) and referred to the internal control DsRed2.
The overall ﬂuorescence signals from the protein–protein interac-
tions VN-Synuclein + Synuclein-VC were signiﬁcantly different from
the noise VN-Synuclein + VC and Synuclein-VC + VN for all three
Synuclein isoforms. Similarly, ﬂuorescence signals from the heterodi-
meric protein–protein interactions VN-xS + zS-VC were signiﬁcantly
higher (P values b 0.001 for all combinations) than the noise from
VN-xS + VC and VN + zS-VC (not shown). These results conﬁrm that
all three, αS, βS, and γS and their respective heterodimers, do have
very similar capabilities to form dimers.
In summary, our data provide evidence, that the dimerization of αS,
βS, and γS may be investigated by quantiﬁcation of ﬂuorescence com-
plementation and determination of signal-to-noise ratios from a large
number of cells. Although human αS and somewhat delayed also βS
were shown to form substantial amount of proteinase K-resistant
aggregates whereas only very minor γS deposits were observed [42],
the dimerization properties of γS are very similar to that of αS and βS.
Thus, it seems likely that dimerization properties of Synucleins do not
reﬂect their propensity to aggregate, but that formation of higher-
order structures like ﬁbrils depends on events acting at the levels of
oligomers or larger structures.
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